top of page
  • Recruiting

NCT04722146: Phase 1b - Teclistamab With Other Anticancer Therapies in Participants With Myeloma

Updated: Sep 16, 2022

NCT04722146: Phase 1b - Teclistamab With Other Anticancer Therapies in Participants With Myeloma

Newly Diagnosed Multiple Myeloma

Relapsed Refractory Multiple Myeloma

teclistamab MAJESTEC STUDY

The purpose of this study is to characterize the safety and tolerability of teclistamab when administered in different combination regimen and to identify the optimal dose(s) of teclistamab combination regimens.


Multiple Locations

International Study Identifier: NCT04722146

Official Title: A Multi-arm Phase 1b Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma

First Posted : January 25, 2021

Click here for details on


Anti-CD3/Anti-BCMA Bispecific Monoclonal Antibody JNJ-64007957

JNJ 64007957






* Bortezomib (Velcade)

* Lenalidomide (Revlimid)

* Pomalidomide(Pomalyst)

* Daratumumab (Darzalex)


- Alabama: University of Alabama at Birmingham

- California: University of California San Francisco

- Georgia: Emory University Atlanta

- Indiana: Indiana University Indianapolis

- Missouri: Washington University School of Medicine Saint Louis

- New York: Memorial Sloan-Kettering Cancer Center New York

- New York: Tisch Cancer Institute Mount Sinai Hospital New York

- New York: New York Presbyterian / Weill Cornell Medical College New York

- New Jersey: Hackensack University Medical Center

- North Carolina: Levine Cancer Institute Charlotte

- Pennsylvania: University of Pittsburgh Medical Center

- Tennessee: Sarah Cannon Research Institute Nashville

- Washington: Seattle Cancer Care Alliance

- Wisconsin: Medical College Of Wisconsin Milwaukee



United States, Alabama

United States, California

United States, Colorado

United States, Georgia

United States, Indiana

United States, Kansas

United States, Missouri

United States, New Jersey

United States, New York

United States, North Carolina

United States, Pennsylvania

United States, Tennessee

United States, Washington

United States, Wisconsin


United Kingdom







NCT03145181: Phase 1 - Teclistamab, Humanized BCMA*CD3 Bispecific Ab, in Relapsed Myeloma (MajesTEC1)

NCT04557098: Phase 2- Teclistamab, in Participants With Relapsed or Refractory Myeloma (MajesTEC-1)

NCT05083169: Phase 3 - Tec-Dara Vs DPd Vs DVd in Relapsed or Refractory Myeloma - (MajesTEC-3)

NCT05243797: Phase 3: Tec + Len Vs Len Alone in NDMM as Maintenance Therapy Post ASCT (MajesTEC-4)

NCT05231629: Phase 2: Sequential Therapy in Multiple Myeloma Guided by MRD Assessments (MASTER-2)



NCT03399799: Phase 1 - Talquetamab, a Humanized GPRC5D x CD3 Bis Ab - Ref MM - MonumenTAL-1

NCT04634552: Phase 2 - A Study of Talquetamab in Participants With Refractory Multiple Myeloma

NCT05050097: Phase 1 - A Study of Talquetamab With Other Anticancer Therapies in Multiple Myeloma

NCT04773522: Phase 1 - JNJ-64407564 in Japanese Participants With Relapsed or Refractory Myeloma



NCT04586426: Phase 1b - Talquetamab and Teclistamab in Relapsed or Refractory Multiple Myeloma

NCT04108195: Phase 1b - Subcutaneous Dara With Bispecific T Cell Redirection Antibodies - TRIMM-2


Posts Archive
bottom of page